跳至主要内容
临床试验/NCT05478356
NCT05478356Unknown不适用

The Effects of Low-dose Atropine and Orthokeratology in Pediatric Myopia Control

Evidence Based Cataract Study Group2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
2
主要终点
Progression of myopia

研究概览

简要总结

Both orthokeratology and atropine eye drops are effective methods for myopia control, but few studies have compared them all together simultaneously. Therefore, the primary aim of the present study was to compare the effect of orthokeratology versus low-dose (0.01% and 0.02%) atropine on the control of myopia progression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
8 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Best corrected visual acuity less then 0.00 log MAR (minimum angle of resolution) units Cycloplegic SER of - 1.0 D or less in both eyes. An inter-eye cycloplegic SER difference of 1.00 D or more.

排除标准

  • Children with cycloplegic cylinder refraction of more than + 1.00 D or less than - 1.00 D.
  • History of binocular vision problems, including strabismus. History of known ocular disorders, including media opacities, macular dysgenesis, optic nerve hypoplasia, perinatal brain injury, buphthalmos, and retinopathy of prematurity.
  • History of medication use that might have affected the refractive results. Systemic or developmental problems that might have hindered refractive development.

研究组 & 干预措施

orthokeratology group

Experimental

干预措施: orthokeratology (Device)

low-dose atropine group

Active Comparator

干预措施: low-dose atropine eye drops (Drug)

结局指标

主要结局

Progression of myopia

时间窗: 1 year

The change of myopia (Ds)

Progression of axial length

时间窗: 1 year

The change of axial length (mm)

次要结局

未报告次要终点

研究者

发起方
Evidence Based Cataract Study Group
申办方类型
Other
责任方
Principal Investigator
主要研究者

Peng ZHOU

Doctor

Evidence Based Cataract Study Group

研究点 (2)

Loading locations...

相似试验